Show simple item record

dc.contributor.authorAndersen, Maria Karoline
dc.contributor.authorRise, Kjersti
dc.contributor.authorGiskeødegård, Guro F.
dc.contributor.authorRichardsen, Elin
dc.contributor.authorBertilsson, Helena
dc.contributor.authorStørkersen, Øystein
dc.contributor.authorBathen, Tone Frost
dc.contributor.authorRye, Morten Beck
dc.contributor.authorTessem, May-Britt
dc.date.accessioned2018-10-05T11:28:23Z
dc.date.available2018-10-05T11:28:23Z
dc.date.created2018-09-30T18:10:13Z
dc.date.issued2018
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/11250/2566656
dc.description.abstractReactive stroma is a tissue feature commonly observed in the tumor microenvironment of prostate cancer and has previously been associated with more aggressive tumors. The aim of this study was to detect differentially expressed genes and metabolites according to reactive stroma content measured on the exact same prostate cancer tissue sample. Reactive stroma was evaluated using histopathology from 108 fresh frozen prostate cancer samples gathered from 43 patients after prostatectomy (Biobank1). A subset of the samples was analyzed both for metabolic (n = 85) and transcriptomic alterations (n = 78) using high resolution magic angle spinning magnetic resonance spectroscopy (HR-MAS MRS) and RNA microarray, respectively. Recurrence-free survival was assessed in patients with clinical follow-up of minimum five years (n = 38) using biochemical recurrence (BCR) as endpoint. Multivariate metabolomics and gene expression analysis compared low (≤15%) against high reactive stroma content (≥16%). High reactive stroma content was associated with BCR in prostate cancer patients even when accounting for the influence of Grade Group (Cox hazard proportional analysis, p = 0.013). In samples with high reactive stroma content, metabolites and genes linked to immune functions and extracellular matrix (ECM) remodeling were significantly upregulated. Future validation of these findings is important to reveal novel biomarkers and drug targets connected to immune mechanisms and ECM in prostate cancer. The fact that high reactive stroma grading is connected to BCR adds further support for the clinical integration of this histopathological evaluation.nb_NO
dc.language.isoengnb_NO
dc.publisherNature Publishing Groupnb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleIntegrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stromanb_NO
dc.title.alternativeIntegrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stromanb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.journalScientific Reportsnb_NO
dc.identifier.doi10.1038/s41598-018-32549-1
dc.identifier.cristin1616320
dc.relation.projectEU 758306
dc.description.localcode© The Author(s) 2018. This article is licensed under a Creative Commons Attribution 4.0 International License.nb_NO
cristin.unitcode194,65,25,0
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for sirkulasjon og bildediagnostikk
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal